Loading
Zantac (ranitidine) cancer litigation illustrates how, in a drug case that depends on general causation, the case can pivot on one practical question: will the court admit the expert proof? In the Zantac record, once general-causation opinions were challenged under Rule 702-style standards, the admissibility rulings shaped what evidence was left to support the specific theories the courts were actually asked to evaluate.
From December 2022 through July 2025, courts reached different results at different procedural stages on the same core dispute: whether ranitidine can generate N-Nitrosodimethylamine (NDMA) under conditions that matter in real use, and whether the scientific record supports a reliable general-causation inference. In the federal Zantac MDL, the court granted the defendants’ general-causation Daubert motions for the designated cancer theories it addressed and granted summary judgment on those designated theories because plaintiffs lacked admissible general-causation proof. In Delaware, the trial court initially denied exclusion motions in an earlier posture, allowing the coordinated docket to proceed past that stage. But on July 10, 2025, the Delaware Supreme Court reversed and emphasized active gatekeeping under Delaware Rule of Evidence 702, with admissibility decided by the judge under Delaware Rule of Evidence 104(a). Once expert testimony is challenged, the proponent bears the burden to establish the sufficiency and reliability requirements by a preponderance of the evidence.
This guide draws practical lessons from those rulings. The 2026 takeaway is straightforward: outcomes often turn on methodology, fit, and record discipline. Put another way, can the proponent show, step by step, that the expert’s approach is reliable and that it was reliably applied to ranitidine-specific facts?
A central scientific question in the Zantac litigation is whether ranitidine can form NDMA under conditions that matter for storage and real-world use, including effects over time and higher-than-room-temperature storage conditions. The FDA requested that manufacturers withdraw ranitidine products from the U.S. market on April 1, 2020, explaining that NDMA impurity levels in some ranitidine products can increase over time and when stored at higher than room temperature.
NDMA’s regulatory classification is part of the backdrop experts and courts have to navigate. EPA’s IRIS assessment classifies NDMA as B2, a “probable human carcinogen.” ATSDR’s NDMA ToxFAQs notes that DHHS classifies NDMA as reasonably anticipated to be a human carcinogen, EPA categorizes it as a probable human carcinogen (Group 2B), and IARC classifies it as probably carcinogenic to humans (Group 2A). These classification systems are not identical, but they provide context for why parties focus so heavily on how, when, and at what levels NDMA might form from ranitidine, and how that evidence is used to support or attack a general-causation inference. None of these classifications resolves the litigation questions by itself.
Delaware’s 2025 Zantac expert-testimony reversal reinforced rigorous judicial gatekeeping for general-causation opinions involving ranitidine, NDMA exposure, and alleged cancer risks. This article explains how the Delaware Supreme Court’s ruling and earlier federal Zantac decisions highlight the importance of product-specific causation, dose and exposure comparability, transparent study selection, reliable methodology, and a clear analytical bridge between scientific evidence and an expert’s conclusions.
Drug Regulation
Causation Analysis
Laboratory Testing
Litigation Support
Patent Dispute
Zantac (ranitidine) cancer litigation illustrates how, in a drug case that depends on general causation, the case can pivot on one practical question: will the court admit the expert proof? In the Zantac record, once general-causation opinions were challenged under Rule 702-style standards, the admissibility rulings shaped what evidence was left to support the specific theories the courts were actually asked to evaluate.
From December 2022 through July 2025, courts reached different results at different procedural stages on the same core dispute: whether ranitidine can generate N-Nitrosodimethylamine (NDMA) under conditions that matter in real use, and whether the scientific record supports a reliable general-causation inference. In the federal Zantac MDL, the court granted the defendants’ general-causation Daubert motions for the designated cancer theories it addressed and granted summary judgment on those designated theories because plaintiffs lacked admissible general-causation proof. In Delaware, the trial court initially denied exclusion motions in an earlier posture, allowing the coordinated docket to proceed past that stage. But on July 10, 2025, the Delaware Supreme Court reversed and emphasized active gatekeeping under Delaware Rule of Evidence 702, with admissibility decided by the judge under Delaware Rule of Evidence 104(a). Once expert testimony is challenged, the proponent bears the burden to establish the sufficiency and reliability requirements by a preponderance of the evidence.
This guide draws practical lessons from those rulings. The 2026 takeaway is straightforward: outcomes often turn on methodology, fit, and record discipline. Put another way, can the proponent show, step by step, that the expert’s approach is reliable and that it was reliably applied to ranitidine-specific facts?
A central scientific question in the Zantac litigation is whether ranitidine can form NDMA under conditions that matter for storage and real-world use, including effects over time and higher-than-room-temperature storage conditions. The FDA requested that manufacturers withdraw ranitidine products from the U.S. market on April 1, 2020, explaining that NDMA impurity levels in some ranitidine products can increase over time and when stored at higher than room temperature.
NDMA’s regulatory classification is part of the backdrop experts and courts have to navigate. EPA’s IRIS assessment classifies NDMA as B2, a “probable human carcinogen.” ATSDR’s NDMA ToxFAQs notes that DHHS classifies NDMA as reasonably anticipated to be a human carcinogen, EPA categorizes it as a probable human carcinogen (Group 2B), and IARC classifies it as probably carcinogenic to humans (Group 2A). These classification systems are not identical, but they provide context for why parties focus so heavily on how, when, and at what levels NDMA might form from ranitidine, and how that evidence is used to support or attack a general-causation inference. None of these classifications resolves the litigation questions by itself.
In the Zantac record, expert disputes commonly focus on issues such as:
Once an admissibility challenge is raised, the gatekeeping question is whether the opinion is reliable enough, and tied closely enough to the case facts, to help the factfinder. The timing can vary by judge and scheduling order, but the key point is the same: admissibility is resolved by the court as a gatekeeping matter, on the schedule set by the court, not left for the jury to fill later.
On December 6, 2022, the MDL court issued an omnibus order granting the defendants’ general-causation Daubert motions for the designated cancer theories addressed by the order (the “Designated Cancers” track). The court also granted summary judgment on those designated theories, reasoning that without admissible primary general-causation evidence, those claims could not proceed. The bottom line was straightforward: without admissible general causation for the designated theories the court addressed, those designated-cancer claims did not get to a jury.
In Delaware’s coordinated docket, the Superior Court denied the parties’ competing motions to exclude expert testimony at that stage of the proceedings. The order followed discovery and a three-day Daubert hearing, along with extensive briefing and submissions. The ruling addressed admissibility under Delaware Rule of Evidence 702 at that stage, not the ultimate merits of any individual plaintiff’s claim.
On July 10, 2025, the Delaware Supreme Court reversed on interlocutory review and emphasized rigorous judicial gatekeeping under Delaware Rule of Evidence 702. For 2026 motion practice, two points are especially practical:
In plain terms, the Court wanted the reasoning laid out in a way that could be tested, not a conclusion that depended on gaps the jury would be asked to fill.
The details differ from case to case, but the Zantac rulings highlight several recurring pressure points in general-causation litigation.
Even if NDMA is classified as a probable human carcinogen, that alone does not establish that ranitidine causes the cancers at issue. The analysis has to connect the product to the agent and the agent to the claimed outcome in a way the court can evaluate. A defensible chain of reasoning often includes questions like:
When one of these steps is missing, handled with assumptions that do not match the record, or treated as obvious, exclusion risk rises.
The Zantac record also shows why dose, duration, and comparability arguments are hard to avoid. This does not always mean a single numeric cutoff, but it does mean the report should deal with fit in a concrete way. If an opinion relies on studies involving materially different exposures, the report should explain why the comparison still holds. That often means grappling with differences in dose ranges, routes of exposure, duration, and the specific conditions used in testing or assumed in modeling. It also means being honest about uncertainty and showing how it was handled.
Courts may accept weight-of-the-evidence approaches, but only when the expert can explain the weights and apply them consistently. The risk is unexplained weighting, shifting criteria, or conclusions that outrun the underlying dataset. If a report uses a weight-of-the-evidence approach, it should be able to answer basic questions clearly: which studies were included, which were excluded, why those choices were made, and whether the same rules were applied consistently across favorable and unfavorable evidence.
Even when a method is accepted in the abstract, it can still be excluded if it is not reliably applied to the facts of the case. That is where reports often become vulnerable: assumptions not supported by discovery, testing protocols that do not reflect relevant conditions, and failure to deal with important alternative explanations that could change the conclusion.
Before reports harden, pressure-test the opinion the way you expect the court to do:
If you cannot explain the link clearly in briefing, it is risky to assume the court will let the jury fill in the gaps.
Is Zantac still on the market in the United States?
No. The FDA requested that manufacturers withdraw ranitidine products from the U.S. market on April 1, 2020, citing concerns about NDMA impurity levels that can increase over time and when stored at higher than room temperature. This answer is specific to ranitidine-containing products in the United States.
What did the Delaware Supreme Court emphasize in 2025?
It reinforced that trial courts must actively gatekeep under Delaware Rule of Evidence 702. It also emphasized that admissibility is a judicial decision once expert testimony is challenged, and that the proponent must show admissibility by a preponderance of the evidence under Delaware Rule of Evidence 104(a).
Why did the federal MDL outcome matter so much?
Because the MDL court excluded plaintiffs’ general-causation experts for the designated cancer theories addressed by the omnibus order, leaving plaintiffs without admissible general-causation proof for those designated theories. That posture supported summary judgment tied to the lack of admissible general-causation evidence for the designated theories. In a May 15, 2023 order entering summary judgment under Rule 56(f), the court explained that summary judgment followed because plaintiffs lacked reliable general-causation evidence after the court granted Daubert motions and excluded their general-causation experts.
What is the 2026 takeaway for expert strategy in drug mass torts?
These rulings suggest courts will want a clear reliability record: documented assumptions, exposure comparability analysis, transparent study selection, and a step-by-step explanation that connects evidence to conclusions without analytical leaps.
In the Zantac record, expert disputes commonly focus on issues such as:
Once an admissibility challenge is raised, the gatekeeping question is whether the opinion is reliable enough, and tied closely enough to the case facts, to help the factfinder. The timing can vary by judge and scheduling order, but the key point is the same: admissibility is resolved by the court as a gatekeeping matter, on the schedule set by the court, not left for the jury to fill later.
On December 6, 2022, the MDL court issued an omnibus order granting the defendants’ general-causation Daubert motions for the designated cancer theories addressed by the order (the “Designated Cancers” track). The court also granted summary judgment on those designated theories, reasoning that without admissible primary general-causation evidence, those claims could not proceed. The bottom line was straightforward: without admissible general causation for the designated theories the court addressed, those designated-cancer claims did not get to a jury.
In Delaware’s coordinated docket, the Superior Court denied the parties’ competing motions to exclude expert testimony at that stage of the proceedings. The order followed discovery and a three-day Daubert hearing, along with extensive briefing and submissions. The ruling addressed admissibility under Delaware Rule of Evidence 702 at that stage, not the ultimate merits of any individual plaintiff’s claim.
On July 10, 2025, the Delaware Supreme Court reversed on interlocutory review and emphasized rigorous judicial gatekeeping under Delaware Rule of Evidence 702. For 2026 motion practice, two points are especially practical:
In plain terms, the Court wanted the reasoning laid out in a way that could be tested, not a conclusion that depended on gaps the jury would be asked to fill.
The details differ from case to case, but the Zantac rulings highlight several recurring pressure points in general-causation litigation.
Even if NDMA is classified as a probable human carcinogen, that alone does not establish that ranitidine causes the cancers at issue. The analysis has to connect the product to the agent and the agent to the claimed outcome in a way the court can evaluate. A defensible chain of reasoning often includes questions like:
When one of these steps is missing, handled with assumptions that do not match the record, or treated as obvious, exclusion risk rises.
The Zantac record also shows why dose, duration, and comparability arguments are hard to avoid. This does not always mean a single numeric cutoff, but it does mean the report should deal with fit in a concrete way. If an opinion relies on studies involving materially different exposures, the report should explain why the comparison still holds. That often means grappling with differences in dose ranges, routes of exposure, duration, and the specific conditions used in testing or assumed in modeling. It also means being honest about uncertainty and showing how it was handled.
Courts may accept weight-of-the-evidence approaches, but only when the expert can explain the weights and apply them consistently. The risk is unexplained weighting, shifting criteria, or conclusions that outrun the underlying dataset. If a report uses a weight-of-the-evidence approach, it should be able to answer basic questions clearly: which studies were included, which were excluded, why those choices were made, and whether the same rules were applied consistently across favorable and unfavorable evidence.
Even when a method is accepted in the abstract, it can still be excluded if it is not reliably applied to the facts of the case. That is where reports often become vulnerable: assumptions not supported by discovery, testing protocols that do not reflect relevant conditions, and failure to deal with important alternative explanations that could change the conclusion.
Before reports harden, pressure-test the opinion the way you expect the court to do:
If you cannot explain the link clearly in briefing, it is risky to assume the court will let the jury fill in the gaps.
Is Zantac still on the market in the United States?
No. The FDA requested that manufacturers withdraw ranitidine products from the U.S. market on April 1, 2020, citing concerns about NDMA impurity levels that can increase over time and when stored at higher than room temperature. This answer is specific to ranitidine-containing products in the United States.
What did the Delaware Supreme Court emphasize in 2025?
It reinforced that trial courts must actively gatekeep under Delaware Rule of Evidence 702. It also emphasized that admissibility is a judicial decision once expert testimony is challenged, and that the proponent must show admissibility by a preponderance of the evidence under Delaware Rule of Evidence 104(a).
Why did the federal MDL outcome matter so much?
Because the MDL court excluded plaintiffs’ general-causation experts for the designated cancer theories addressed by the omnibus order, leaving plaintiffs without admissible general-causation proof for those designated theories. That posture supported summary judgment tied to the lack of admissible general-causation evidence for the designated theories. In a May 15, 2023 order entering summary judgment under Rule 56(f), the court explained that summary judgment followed because plaintiffs lacked reliable general-causation evidence after the court granted Daubert motions and excluded their general-causation experts.
What is the 2026 takeaway for expert strategy in drug mass torts?
These rulings suggest courts will want a clear reliability record: documented assumptions, exposure comparability analysis, transparent study selection, and a step-by-step explanation that connects evidence to conclusions without analytical leaps.
Drug Regulation
Causation Analysis
Laboratory Testing
Litigation Support
Patent Dispute
Expert Witness Guides
Expert Witness Guides
